Novel Compound Shows Promise for Treatment of ... ( BIRMINGHAM Ala. Sept. 11 --- Sou...)

Novel Compound Shows Promise for Treatment of Alcoholism

Date:9/11/2008

BIRMINGHAM, Ala., Sept. 11 /PRNewswire-USNewswire/ --- Southern Research Institute and Gallo Research Center today announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry. The publication is available online today at the journal's website, and suggests that a new compound that causes selective and long-lasting reduction in ethanol consumption might be a promising candidate as a novel treatment for alcoholism.

The article, "A Novel Delta Opioid Receptor Antagonist, SoRI-9409, Produces a Selective and Long-Lasting Decrease in Ethanol Consumption in Heavy-Drinking Rats" by Selena Bartlett, BPharm PhD, Director of Preclinical Development Group at the Gallo Research Center at University of California San Francisco, et al presents the effects of SoRI-9409 on ethanol consumption. These are promising developments for the treatment of alcoholism. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) estimates 15.1 million people are alcohol-abusing or alcohol-dependent individuals. There are currently only three FDA-approved options for the treatment of alcoholism.

The compound, SoRI-9409, was first designed and synthesized in Southern Research's Drug Discovery research division by Dr. Subramaniam (Sam) Ananthan under U.S. Government Grant DA008883. "Southern Research has been particularly interested in ligands that interact with opioid delta receptor subtype since such ligands hold promise as therapeutic agents for treatment of drug addictions and other disorders," said Dr. Ananthan, senior scientist and manager of Computational Chemistry and CNS Discovery Chemistry at Southern Research Institute. "The present findings by Dr. Bartlett and her group on the effect of SoRI-9409 on its ability to reduce alcohol intake not only provides us with a new drug lead, but also serves as the impetus for further research aimed at
'/>"/>

SOURCE Southern Research Institute
Copyright©2008 PR Newswire.
All rights reserved

9

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
2. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
6. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
7. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
8. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

Post Your Comments:

(Date:6/19/2013)... , June 19, 2013 Eli Lilly and ... alert about two illegal scams, purportedly using the name ... that are actively targeting the public through postal mail ... have no connection to any foreign lottery organizations and ... by the job-seeking victims of the scam. The activities ...

(Date:6/19/2013)... YORK , June 19, 2013 ... that a new market research report ... Partnerships, Licensing, Investments and ... 2013 in Pharmaceuticals http://www.reportlinker.com/p0925641/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-for-May-2013-in-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking ... Investments and M&A Deals and Trends ...

(Date:6/19/2013)... 2013 Ellen MacArthur Foundation ... tre åren kommer att vara en partner för ... ekonomi. Efter stiftelsens framgångsrika partnerskap med ... kommer Philips att ansluta sig som partner för ... sin egen verksamhet och stödja stiftelsens arbete inom ...

[0] Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests [0] Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals [0] Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi

... NewCardio, Inc., (OTC Bulletin Board: NWCI ... the Company has been invited to present the results ... upcoming conference entitled "Cardiovascular Safety in Drug Development: State-of-the-Art ... (FDA), the Cardiac Safety Research Consortium (CSRC) and the ...

... ICU Medical, Inc. (Nasdaq: ICUI ) ... release of the MicroCLAVE Clear Neutral Displacement Needlefree Connector ... Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas. ... verifying effective flushing of the patient catheter after use ...

Cached Medicine Technology:NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 2 NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 3 NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 4 NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 5 NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 6 ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas 2 ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas 3

NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas

(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...

(Date:6/19/2013)... Amber Roberson with the Robert ... Native Care Health, LLC and Medcase, LLC, became ... (NAHU) new professional development course on the Patient ... education course for agents has been approved in ... education credits from the Missouri Department of Insurance. ...

(Date:6/19/2013)... June 19, 2013 As Januvia ... continue to mount in courts throughout the U.S., Bernstein ... Administration (FDA) recently held a meeting to discuss the ... incretin mimetics. According to a June 12th report ... the makers of Januvia and similar drugs, following a ...

(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...

(Date:6/19/2013)... by researchers at The University of Texas MD Anderson ... remarkable promise for the treatment of relapsed or refractory ... findings of the 18-center Phase 2 study were published ... . Previous interim findings were presented in December 2012 ... and Exposition. , Unprecedented results, fewer side ...

Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2 Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3 Health News:RWI Benefits, LLC Becomes PPACA Certified 2 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2 Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3 Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2 Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2

[0] Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent [0] RWI Benefits, LLC Becomes PPACA Certified [0] Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics [0] Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines [0] Ibrutinib continues strong showing against mantle cell lymphoma

... in Comprehensive Report Comparing SSO and ... Healthcare Industry, ANDOVER, Mass., March 19 ... Sign-On (SSO), announced today that it ranked ... comparing SSO and,context management vendors performance. The ...

... in German . , Transport processes in ... on the roads. Molecular motors, which are special protein molecules, ... and transport it along microtubules, which are the roads of ... smaller than trucks and can only move as far as ...

... 19 To develop new strategies to control tuberculosis ... worlds population and kills almost two million people every ... has received an $11.4 million grant from the Bill ... researchers to use new imaging technologies to study TB ...

... 19 Mirion Technologies, the,leading global provider of ... industry, will showcase two new products at the,10th ... from,March 25th - 28th., Mirion,s Health Physics ... Contamination Monitor. The TwoStep Exit monitor is a,new ...

... be at the forefront of fighting cancer thanks to ... Research Foundation (ACRF). , The ACRF funding will ... and Metabolic Medicine (DI), and their partners from the ... tools to help them discover genes linked to cancer. ...

... are more respectful, SAN DIEGO, March 19 Over ... one to three years, find a non-nursing,job, work part-time, or ... by AMN Healthcare, the largest health care staffing firm in,the ... many baby,boomer nurses may be facing career burn-out. About 46 ...

Cached Medicine News:Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 2 Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 3 Health News:Tug of war in the cells 2 Health News:Tug of war in the cells 3 Health News:Stopping a deadly killer 2 Health News:Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition 2 Health News:Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years 2

Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report Tug of war in the cells Stopping a deadly killer Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition Queensland researchers get the latest tools to fight cancer Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Adenovirus Antibody, IgM Adenovirus Antibodies, IgG & IgM Adenosine Deaminase, RBC Adderall